Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) EBITDA (2017 - 2025)

Autolus Therapeutics (AUTL) has disclosed EBITDA for 6 consecutive years, with -$84.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBITDA fell 54.12% year-over-year to -$84.9 million, compared with a TTM value of -$228.8 million through Sep 2025, up 3.58%, and an annual FY2024 reading of -$220.8 million, down 11.27% over the prior year.
  • EBITDA was -$84.9 million for Q3 2025 at Autolus Therapeutics, down from -$29.0 million in the prior quarter.
  • Across five years, EBITDA topped out at -$4.0 million in Q4 2022 and bottomed at -$84.9 million in Q3 2025.
  • Average EBITDA over 4 years is -$49.9 million, with a median of -$55.1 million recorded in 2024.
  • The sharpest move saw EBITDA crashed 1721.06% in 2023, then skyrocketed 49.43% in 2025.
  • Year by year, EBITDA stood at -$4.0 million in 2022, then plummeted by 1721.06% to -$72.4 million in 2023, then grew by 22.78% to -$55.9 million in 2024, then crashed by 51.92% to -$84.9 million in 2025.
  • Business Quant data shows EBITDA for AUTL at -$84.9 million in Q3 2025, -$29.0 million in Q2 2025, and -$59.1 million in Q1 2025.